Analysis of systemic barriers to medical innovation and pharmaceutical development

The article argues that medical progress is currently constrained by excessive bureaucratic oversight and profit-driven corporate incentives. It suggests that regulatory adjustments could significantly accelerate the pace of pharmaceutical and medical innovation, though it lacks specific policy proposals or empirical data to support these claims.